Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 313

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 313
---
ot”) on April 21, 2016 and July 14, 2016, all as amended on May                  
  5, 2019, pursuant to which the Company is obligated to pay Ramot a fixed royalty of 2.5% on net sales of all of the Company’s products        
  (as defined in the agreement) by the Company and its affiliates, with no set maximum. The royalty will be payable as of the first commercial  
  sale (as defined in the agreement), until the later of: 15 years; or until the last to expire of the patents or patent applications from      
  research developed at Tel Aviv University and assigned to the Company, on a country-by-country, product-by-product basis. The Company         
  is also obligated to pay a 7% royalty (and in no event less than 0.65% of the net sales of Company products sold by the Company’s             
  licensees in a given year) on any royalties or revenues received by the Company from its licensees.                                           
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Under an Operations Partner Agreement between the Company and services provider HekaBio K. K. of May 21,                                                                                              

  On November 18, 2018 and July 29, 2019, the Company entered into research and license agreements with                                           
  BGN Technologies, the technology transfer company of Ben Gurion University (“ BGN”), further amended on May 12, 2021, wherein                   
  the Company will wholly own any intellectual property that is developed jointly by Ben Gurion University and others (including the Company),    
  and BGN will receive 0.75% royalties on all sales of the Company’s alpha radiation products, net of certain deductions and irrespective         
  of the intellectual property underlying such sales, or 1.5% royalties on sales of products that contain intellectual property owned by          
  Ben Gurion University, net of certain deductions. BGN will receive 4% of license revenues (as defined in the agreements) that relate to         
  jointly developed intellectual property, and 8% of license revenues that relate to intellectual property developed solely by Ben Gurion         
  University. The parties also agreed that the Company will continue to conduct research at Ben Gurion University for as long as the researchers  
  wish to, and the parties have agreed on a research budget in good faith.                                                                        
 ─